On October 14, 2025, Atossa Therapeutics announced the appointment of Mark Daniel, CPA, as its new Chief Financial Officer. The move comes as the company prepares to transition from a clinical‑stage biopharmaceutical to a commercial‑ready organization focused on bringing its lead candidate, Z‑endoxifen, to market.
Daniel brings more than 25 years of experience in life‑science finance, having built forecasting cadences, revenue‑forecasting systems, and public‑company controls for large global life‑science businesses. He has overseen weekly revenue forecasting, managed operating‑expense budgets exceeding $200 million, implemented Sarbanes‑Oxley controls, and delivered over $50 million in cost savings. His treasury and capital‑markets expertise includes managing a $400 million cash portfolio and executing nearly $1 billion in equity, convertible‑debt, and credit transactions.
With Daniel on board, Atossa will focus on establishing revenue‑ready systems, disciplined spend, and milestone‑aligned financing. The company’s CEO, Steven Quay, emphasized that the new CFO’s playbook will support the planned launch path for Z‑endoxifen, ensuring that financial operations are aligned with commercial objectives and that liquidity is maintained as the company moves toward market entry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.